WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
Guidelines for District Health Managers
Le présent guide a été conçu comme un outil simple et pratique pour aider les administrateurs sanitaires des districts à élaborer un plan réaliste à leur niveau, afin de mieux gérer l'élimination des déchets produits par les injectio
This guide to local production of WHO-recommended handrub formulations is separated into two discrete but interrelated sections:
Part A provides a practical guide for use at the pharmacy bench during the actual preparation of the formulation. Users may want to display the material on the wall of ...the production unit.
Part B summarizes some essential background technical information and is taken from WHO Guidelines on Hand Hygiene in Health Care (2009). Within Part B the user has access to important safety and cost information and supplementary material relating to dispensers and distribution.
more
La concentration en éthanol est mesurée par une méthode densitométrique à l’aide d’un alcoomètre Gay LUSSAC à l’échelle v/v.
This e-tool is intended for use by people in charge of occupational health and safety for health workers at the national, subnational and facility levels and for health workers who want to know what WHO and ILO recommend for the protection of their health and safety
Poster for communities and health worker
The integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD)
Want to build a tippy tap? Want to teach someone else how to? Here is a graphical manual that works for both literate and illiterate populations. If you need a particular language that’s not here or can assist with translation, please let us know!
Accessed 18 December 2014
Creating Videos to train health workers and serve communities.
Global Health Media Project designs and develops videos that are tailored to the needs of health workers and populations in low-resource settings. Internet and mobile technology give us the power to reach large numbers, cost-effectively... and across vast distances, resulting in significant impact at minimal cost per patient.
more
WHO has developed standardized health kits of medicines and medical supplies to meet different health needs in humanitarian emergencies and disasters.
These kits are developed to provide reliable and affordable medicines and supplies quickly to those in need. The kits are used by United Nations age...ncies, nongovernmental organizations and national governments.
Based primarily on WHO’s Essential Medicines list and guidelines on treatment of specific medical conditions, the contents of the kits are frequently reviewed and updated to adapt to changing needs based on experience in emergency situations.
A certain number of kits are prepositioned in strategic locations to be mobilized quickly in times of need. Long term agreements with suppliers are also in place to ensure rapid shipment wherever needed.
more